Akanda Corp.

NasdaqCM:AKAN Stock Report

Market Cap: US$7.9m

Akanda Past Earnings Performance

Past criteria checks 0/6

Akanda's earnings have been declining at an average annual rate of -36.9%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been declining at an average rate of 8% per year.

Key information

-36.89%

Earnings growth rate

-199.61%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate-7.99%
Return on equityn/a
Net Margin-17,886.87%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Seeking Alpha Sep 26

Akanda gains ahead of plans for first shipment of medical cannabis to Germany

Akanda (NASDAQ:AKAN) prepares for first export shipment from its Portugal-based Holigen operation in the coming weeks. The company’s EU GMP certified indoor grow facility in Sintra received its first purchase order and is expected to make its first export shipment to Germany imminently. The company recently entered into an agreement to deliver 1,000 kilograms of high-grade medical cannabis flower to German pharmacies through the Cansativa platform. Cansativa will have a right of first refusal to take on additional quantities that could result in the full capacity utilization of Holigen’s 2,000 kilograms per annum indoor production capacity. The deal ranks as one of the largest supply agreements in the European medical cannabis industry. The company is targeting a leading 10% market share position of German medical cannabis imports, with room for additional expansion and growth.  Shares +3.65% premarket.
Seeking Alpha Sep 08

Akanda adds Aurora Cannabis founder as Chair of advisory board

U.K.-based cannabis player Akanda Corp. (NASDAQ:AKAN) announced Thursday that Terry Booth, the founder of its Canadian rival Aurora Cannabis Inc. (ACB), has joined as Chair of the company’s newly formed Advisory Board. AKAN said that Mr. Booth, a founder of ACB, has given leadership to drive over 30 acquisitions and transactions over the past five years. “Having Terry on board as an advisor is a powerful validation of our strategy and our potential to lead the emerging cannabis market in Europe,” Chief Executive of the company Tej Virk noted. Meanwhile, Mr. Booth drew parallels between AKAN and ACB, adding: “I believe that there is significant potential in Akanda and I see similarities to it and when we were at Aurora in the stages before our explosive growth.” In 2020, Mr. Booth announced his retirement from ACB as its CEO.
Seeking Alpha Aug 24

Akanda adds new hires eyeing European expansion

U.K.-based cannabis cultivator Akanda Corp. (NASDAQ:AKAN) announced the appointment of Tom Flow as its Chief Operating Officer and Steven George as the Commercial Director as the company intends to improve its profitability in the European medical cannabis market. Mr. Flow will also serve as the Managing Director of Holigen Limited, which AKAN acquired from The Flowr Corporation in May 2022. AKAN said he has more than 15 years of direct experience in the cannabis industry, including large-scale EU GMP-certified cultivation facilities. Mr. George, formerly the Iberian Country Manager and European Alliance Manager at Tilray (TLRY), has offered independent advisory services to cannabis clients in Europe since he left the Canadian company. “Adding proven and elite global cannabis executives like Tom and Steven is an important milestone for Akanda, expanding our capabilities and growing our leadership as we scale,” noted AKAN’s Chief Executive Tej Virk.

Revenue & Expenses Breakdown

How Akanda makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:AKAN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 250-4640
30 Sep 250-2440
30 Jun 251-240
31 Mar 251-340
31 Dec 240-340
30 Sep 240-330
30 Jun 240-330
31 Mar 240-430
31 Dec 230-440
30 Sep 232-880
30 Jun 233-12130
31 Mar 233-10170
31 Dec 223-8200
30 Jun 220-7150
31 Mar 220-7100
31 Dec 210-230
31 Dec 200-210

Quality Earnings: AKAN is currently unprofitable.

Growing Profit Margin: AKAN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AKAN is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.

Accelerating Growth: Unable to compare AKAN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.8%).


Return on Equity

High ROE: AKAN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 03:14
End of Day Share Price 2026/07/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akanda Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.